The binding target of Osemozotan is 5-HT1A receptors. Osemozotan binds with almost 1000 times greater affinity to 5-HT1A receptors than to most other 5-HT, dopamine, or adrenergic receptors.[2] With repeated exposure of Osemozotan at the 5-HT1A receptors, there seems to be no change in the number of receptors, which is not typically seen with pharmaceutical
agonists.[14]
Pharmacokinetics
Pharmacokinetic data was collected from animal studies performed in mice and rats. The
CMax was obtained 15 minutes after oral ingestion of Osemozotan, the
area under the curve was 2,943 ng x hr/mL and the
half-life was 1.3 hours.[6] Pharmacokinetic testing has been able to help explain the longer acting pharmacologic effects of Osemozotan, and the increased potency. Osemozotan was shown to have increased duration of pharmacologic effects compared to
azapirones and requires a substantially lower dose to produce its pharmacologic effects.[6] This may be attractive to populations who have to take this medication in that they may not have to take the medication as often throughout the day. In these studies, here was a difference in dosage amount necessary for the indication it is used.[6] Osemozotan has not been found to be metabolized to
1-(2-pyrimidinyl)-piperazine, a common metabolite found with the azapirone class of medications.[6] 1-(2-pyrimidinyl)-piperazine has affinity for receptors other than 5-HT1A, decreasing its specificity and increasing the risk of unwanted effects.[6] Since Osemozotan does not express this metabolite, it has greater specificity to 5-HT1A compared to other anxiolytic medications.
Uses
Osemozotan is being investigated in its usage to treat pain, aggressive behavior, anxiety, depression,
obsessive-compulsive disorder, and drug dependence with methamphetamine and cocaine.[2][6]
Pain
It has been proposed that Osemozotan could be used as an analgesic agent because of its activation of 5-HT 1A receptors that lead to inhibitory serotonin signaling pathway within the spinal cord to cause
hypoalgesia and decrease mechanical
allodynia.[2][15]
Aggressive behavior
Osemozotan was found to decrease the number of fighting incidences[spelling?] in mice similar to
buspirone,
diazepam, and
tandospirone but required a lower pharmacologic dose to produce beneficial effects.[6] Osemozotan showed dose-dependent anti-aggressive effects and was not shown to decrease motor coordination within the mice.[6]
Anxiety and depression
When stimulated, 5-HT 1A receptors are shown to have anxiolytic and antidepressant pharmacologic effects.[2]
Obsessive-Compulsive Disorder (OCD)
OCD patients have been found to have increased 5-HT levels within the brain.[1][16] With the use of Osemozotan as a 5-HT 1A agonist, there is a decrease in serotonergic activity within the brain, leading to possible anti-obsessional pharmacological action.[6] One animal mouse model used to test for OCD is known as the marble burying test, in which the amount of marbles buried within a certain time frame is recorded.[6] Mice performed the marble burying test both with and without Osemozotan. With Osemozotan administration, the number of marbles buried was decreased with apparently little to no loss in motor coordination; these test results support the theory that Osemozotan may be useful in the treatment of OCD.[6]
Drug dependence
It has been noted that
sensitization of cocaine may stem from action of the 5-HT 1A receptor.[10][17] While the role of 5-HT receptors with methamphetamine is still not certain, the use of osemozotan was found to decrease 5-HT levels in patients with repeated methamphetamine exposure; this may be a possibility for treatment of drug dependence with cocaine and methamphetamine.[9]
Prevalence of mental disease states
About 18% of American adults suffer from some type of anxiety disorder, [18] and 1 in 5 adults in the United States are on some type of medication to help control or improve their behavior.[19] The prevalence of prescription medication use for mental illnesses has noticeably increased in the past few years, with increasing numbers in the younger adults and in men.[19] Around 60 billion dollars are spent annually for treatments dealing with mental illnesses.[20]
^Abe M, Tabata R, Saito K, Matsuda T, Baba A, Egawa M (August 1996). "Novel benzodioxan derivative, 5-[3-[((2S)-1,4-benzodioxan-2-ylmethyl) amino]propoxy]-1,3-benzodioxole HCl (MKC-242), with anxiolytic-like and antidepressant-like effects in animal models". The Journal of Pharmacology and Experimental Therapeutics. 278 (2): 898–905.
PMID8768745.
^Sakaue M, Ago Y, Sowa C, Koyama Y, Baba A, Matsuda T (January 2003). "The 5-HT1A receptor agonist MKC-242 increases the exploratory activity of mice in the elevated plus-maze". European Journal of Pharmacology. 458 (1–2): 141–4.
doi:
10.1016/S0014-2999(02)02786-3.
PMID12498918.
^
abcdefghijklAbe, Michikazu, Hiroshi Nakai, Reiko Tabata, Ken-Ichi Saito, and Mitsuo Egawa. "Effect of 5-{3-[((2S)-1,4-Benzodioxan-2-ylmethyl)amino]propoxy}-1,3-benzodioxole HCL (MKC-242), a Novel 5-HT1A-Receptor Agonist, on Aggressive Behavior and Marble Burying Behavior in Mice." Jpn. J. Pharmacol.76 (1998): 297-304.
^Ago Y, Koyama Y, Baba A, Matsuda T (December 2003). "Regulation by 5-HT1A receptors of the in vivo release of 5-HT and DA in mouse frontal cortex". Neuropharmacology. 45 (8): 1050–6.
doi:
10.1016/S0028-3908(03)00304-6.
PMID14614948.
S2CID20463997.
^
abAgo Y, Nakamura S, Uda M, Kajii Y, Abe M, Baba A, Matsuda T (September 2006). "Attenuation by the 5-HT1A receptor agonist osemozotan of the behavioral effects of single and repeated methamphetamine in mice". Neuropharmacology. 51 (4): 914–22.
doi:
10.1016/j.neuropharm.2006.06.001.
PMID16863654.
S2CID38888234.
^
abAgo Y, Nakamura S, Hayashi A, Itoh S, Baba A, Matsuda T (September 2006). "Effects of osemozotan, ritanserin and azasetron on cocaine-induced behavioral sensitization in mice". Pharmacology, Biochemistry, and Behavior. 85 (1): 198–205.
doi:
10.1016/j.pbb.2006.07.036.
PMID16962650.
S2CID1794862.
^Horiguchi N, Ago Y, Hasebe S, Higashino K, Asada K, Kita Y, et al. (November 2013). "Isolation rearing reduces mechanical allodynia in a mouse model of chronic inflammatory pain". Pharmacology, Biochemistry, and Behavior. 113: 46–52.
doi:
10.1016/j.pbb.2013.10.017.
PMID24161684.
S2CID19975118.
^McMillen BA, Scott SM, Williams HL, Sanghera MK (April 1987). "Effects of gepirone, an aryl-piperazine anxiolytic drug, on aggressive behavior and brain monoaminergic neurotransmission". Naunyn-Schmiedeberg's Archives of Pharmacology. 335 (4): 454–64.
doi:
10.1007/bf00165563.
PMID2439924.
S2CID23396992.
^Nakamura S, Ago Y, Hayashi A, Itoh S, Kakuda M, Hashimoto H, et al. (December 2006). "Modification of cocaine-induced behavioral and neurochemical effects by serotonin1A receptor agonist/antagonist in mice". Synapse. 60 (7): 479–84.
doi:
10.1002/syn.20323.
PMID16952156.
S2CID29597138.